To characterize changes in the myocardium in subjects with prediabetes, diabetes, and healthy controls with preserved left ventricular ejection fraction (LVEF) by using cardiac magnetic resonance imaging (CMR) in a sample from the general population. 
Aims
To characterize changes in the myocardium in subjects with prediabetes, diabetes, and healthy controls with preserved left ventricular ejection fraction (LVEF) by using cardiac magnetic resonance imaging (CMR) in a sample from the general population. 
Methods and results
Subjects without history of cardiovascular disease and preserved LVEF but established diabetes, prediabetes, and controls from a population-based cohort underwent contrast-enhanced CMR. Obtained parameters included left ventricular (LV) function and morphology, late gadolinium enhancement as well as T1-mapping and derivation of extracellular volume fraction (ECV) by modified Look-Locker inversion recovery for diffuse fibrosis in a subset of patients. Fibrosis volume and cell volume were calculated and LV remodelling index was calculated by dividing the LV mass by its end-diastolic volume. Among 343 subjects (56.1 ± 9.2 years, 57% males), 47 subjects were classified as diabetes, 78 as prediabetes, and 218 as controls. Haematocrit values and thus ECV parameters were available in 251 subjects. LV remodelling index was significantly higher in participants with prediabetes and diabetes, independent of body mass index (BMI), hypertension, age, and sex. ECV was decreased in subjects with prediabetes and diabetes compared with healthy controls (23.1 ± 2.4% and 22.8 ± 3.0%, both P < 0.007). In contrast, cell volume was significantly higher in subjects with prediabetes and diabetes as compared with controls (109.1 ± 23.8 and † These authors contributed equally to this work.
Introduction
The current epidemic of diabetes affects many individuals in developed and developing countries and the prevalence threatens to increase continuously in the future. 1, 2 Besides diabetes with the established risk for cardiovascular outcomes, there is also a substantial proportion of individuals with impaired glucose metabolism not satisfying diabetes criteria, classified as subjects with prediabetes. 3 These individuals incur an increased risk for progressing to type 2 diabetes or cardiovascular events. 4, 5 One of the major risks associated with diabetes is the development of diabetic cardiomyopathy, defined as myocardial dysfunction in the absence of coronary artery disease and hypertension, which is associated with adverse outcome. 6 In this setting, hyperglycemic states trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition that manifest as altered myocardial relaxation and diastolic dysfunction that can be assessed with imaging technology. 5, 6 Additionally, in a sample of the general population, also other mechanisms such as hypertensive heart disease may trigger the alteration of the myocardium, leading to cardiac hypertrophy and impaired contractile function. 7 Advanced cardiac magnetic resonance imaging (CMR) allows for detailed, non-invasive characterization of the myocardium, including assessment of systolic and diastolic function, viability, and T1 relaxation times using mapping techniques. 8 In particular, T1-relaxation times of the myocardium may represent early changes to the myocardium with respect to diffuse fibrotic deposition. 6 As such, a shorter post-contrast myocardial T1 time, assuming a higher interstitial diffuse myocardial fibrosis in patients with diabetes, seems to be associated with impaired myocardial systolic and diastolic function. 9 Also, T1-mapping parameters, such as native T1 relaxation, quantification of the myocardial partition coefficient k, or extracellular volume fraction (ECV) provide valuable indices for the assessment of diffuse myocardial fibrosis. [10] [11] [12] In addition, the use of contrastenhanced T1 mapping enables derivation of the myocardial intracellular compartment, including cardiac cell volume. 13, 14 While these changes are well known in subjects with impaired left ventricular (LV) ejection fraction (EF), CMR may provide more detailed assessment in subjects particularly in whom left ventricular ejection fraction (LVEF) is preserved. 15 The objective of the present study was to characterize myocardial tissue by using a comprehensive contrast-enhanced CMR protocol in subjects with prediabetes, diabetes and controls without known cardiovascular disease and preserved LVEF in a sample from the general population. Our hypothesis was, that CMR allows for characterization of differences in myocardial tissue composition among subjects with prediabetes, diabetes, and healthy controls.
Methods

Study design
The study was designed as a case control study nested in a prospective cohort from the Cooperative Health Research in the Region of Augsburg (KORA).
Subjects and recruitment procedure
Details on the study design and protocol have been provided elsewhere. 16 Briefly, subjects were recruited from the FF4 follow-up of the KORA S4 study (second follow-up 2013/14 and baseline survey 1999-2001, respectively), a large sample from the general population in the region of Augsburg, Germany. 17 Eligible subjects without prior cardiovascular disease were enrolled in a CMR sub-study, if they had no contraindications to either CMR or gadolinium contrast administration. The study was approved by the institutional review board of the medical faculty of Ludwig-Maximilian University Munich and all participants provided written informed consent.
Covariates
Subjects of the KORA S4 cohort were re-examined between June 2013 and September 2014 at the KORA study centre. 16 An oral glucose tolerance test (OGTT) was administered to all participants and established definitions of diabetes and prediabetes were applied. 18 Specifically, prediabetes was defined as impaired glucose tolerance and/or impaired fasting glucose, healthy controls were defined as normal glucose metabolism by OGTT. 19 Blood pressure was measured in the course of the KORA health study examinations, independent of the time of CMR acquisition. Systolic and diastolic blood pressure (BP) measurements were obtained three times at the right arm of seated participants after a 5-min resting period. The resting period between readings was 3 min. An oscillometric digital BP monitor (HEM-705CP, Omron Corporation, Tokyo, Japan) was used and one of two cuff sizes was applied according to the circumference of the participant's arm. The mean of the second and third BP measurements was used for the present analyses. Hypertension was defined as increased systolic blood pressure > _140 mmHg, increased diastolic blood pressure > _90 mmHg or use of antihypertensive medication under awareness of having hypertension. Other established risk factors were collected in standardized fashion as part of the KORA study design and described elsewhere. 17 In a subset of subjects, blood samples were taken at the time of the examination for the calculation of volume parameters.
Cardiac magnetic resonance imaging
The CMR protocol was embedded in a comprehensive, whole-body exam using a 3 T Magnetom Skyra (Siemens AG, Healthcare Sector, Erlangen, Germany) and details have been described elsewhere. 16 The 20 and late gadolinium enhancement (LGE) sequences 10 min after administration of gadopentetate dimeglumine (0.2 mmol/kg, Gadovist, Bayer Healthcare, Berlin, Germany).
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The MOLLI sequences were acquired on short axis at the midventricular and basal short-axis plane before and 10 min after the application of contrast agent, using the following parameters: Slice thickness 8 mm, spatial resolution: 1.5 Â 1.5 mm LGE was acquired on Fast Low Angle Shot (FLASH) inversion recovery sequences with the following parameters: Slice thickness 8 mm, FOV 300 Â 360 mm, Matrix 256 Â 140, TR 700-1000 ms, TE 1.55 ms, FA .
All analyses were performed in blinded fashion by independent readers unaware of the diabetic status and clinical covariates on dedicated offline workstations.
Left ventricular function
Cine SSFP sequences were evaluated semi-automatically (analysis performed by A.S.) using commercially available software (cvi42, Circle Cardiovascular Imaging, Calgary, Canada). Following automatic contour detection of the LV endocardium, all borders were corrected manually, if necessary (100% of cases). Established LV volumetric data were derived according to current guidelines excluding the papillary muscles. 23 The LV remodelling index was obtained by calculating the ratio of the LV mass to the LV end-diastolic volume.
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Late gadolinium enhancement
Analysis of LGE was performed visually in short-axis stack and a fourchamber view by two experienced readers (HH, TZ) using commercially available software (cvi42, Circle Cardiovascular Imaging, Calgary, Canada) for the presence and distribution pattern (sub-endocardial, mid-myocardial, and epicardial) of LGE using the 17-segment model of the American Heart Association (AHA). 22 In case of disagreement a consensus reading including a senior investigator was performed.
T1-mapping
The myocardium of the LV (inner and outer contour) was segmented in the basal slice and the mid-ventricular slice of the short-axis images ( Figure 1 ) following recommendations to omit influence of surrounding fat or blood (AS, HP). Segments affected with obvious artifacts or presence of LGE were omitted in order to avoid distortions of the measured values. 24, 25 The myocardium was divided in a total of 17 segments using AHA classification; 22 measurements were obtained in segment [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] (basal and mid-ventricular level) in the acquired short-axis images. 22 Another region of interest was placed in the blood volume. ECV as a measure of the amount of the extracellular matrix was calculated from the pertaining T1 relaxation times native and 10 min after the application of the contrast medium by taking into account the haematocrit level. Fibrosis volume and the total cell volume were derived using the following formula:
11,13,14,24,26
blood)
• ECV = (1 -haematocrit level)Âk • Fibrosis volume = ECV*LVmass/myocardial density [myocardial density = 1.05 g/mL]
• Cell volume = ((1 -ECV)*LVmass)/myocardial density
Statistical analysis
Subject demographics, cardiovascular risk factors and CMR outcomes are presented as arithmetic means and standard deviations for continuous variables and counts and percentages for categorical variables. Differences in baseline characteristics according to diabetes status groups were evaluated by one-way ANOVA and v 2 test, respectively, with
Bonferroni-adjustment. Differences between study sample and excluded subjects according to age, sex, and body mass index (BMI) were tested by multivariable logistic regression.
To assess the association between diabetes status and parameters of diffuse myocardial fibrosis, a linear regression model crude and subsequently adjusted for age, sex, BMI, and hypertension was calculated. Diabetes status entered the model as a categorical variable with the three levels control, prediabetes, and diabetes with the control group as the reference group. For each outcome, predicted means with 95% confidence intervals were calculated. For LGE, predicted proportions with 
Results
Among 400 subjects enrolled in the study, the cardiovascular protocol was completed in 368 subjects. After excluding one subject with T1 mapping affected by artefacts in all segments, 17 subjects with incomplete measurements for LV functional parameter and 7 subjects with LVEF < 50%, 343 subjects were included in the analysis; 78 subjects were classified as having prediabetes and 47 subjects had established diabetes mellitus (23 and 14%, respectively). Haematocrit values and thus ECV parameters were available in 251 subjects (184 controls, 39 subjects with prediabetes and 28 subjects with diabetes, respectively), who were younger and less obese than the overall cohort (P = 0.04 and P = 0.01, respectively).
Demographic and risk factors according to diabetes status
Demographic and risk profiles of the study participants are provided in Table 1 . The population were predominantly middle aged males (mean age: 56.1 ± 9.2 years, 57% male). Diabetes status was associated with male sex and age (P = 0.006 and P < 0.001, respectively) and subjects with prediabetes and diabetes had significantly higher BMI than controls (29.9 ± 4.4 and 30.0 ± 5.0 kg/m 2 vs. 26.7 ± 4.2 kg/m 2 , both P < 0.001, respectively). Prevalence of hypertension was significantly higher in subjects with prediabetes or diabetes as compared with healthy controls (44 and 70% vs. 22%, both P < 0.001).
Characterization of myocardial tissue by CMR
Cardiovascular findings stratified by prediabetes, diabetes and controls are provided in Table 2 . The end-diastolic volume index was significantly lower in prediabetes and diabetes as compared with healthy controls (61.0 ± 12.3 and 57.1 ± 12.6 mL/m 2 vs. 69.9 ± 14.5 mL/m 2 ; both P < 0.001). Due to decreased end-diastolic LV volume (P < 0.001) and elevated LV mass in patients with prediabetes and diabetes compared with the control group (P = 0.97 and P = 0.05, respectively), LV remodelling index was significantly higher in participants with prediabetes and diabetes as compared with controls (1.21 ± 0.27 and 1.37 ± 0.38 g/mL, vs. 1.03 ± 0.24 g/mL, both P < 0.001) and elevated in subjects with diabetes as compared with subjects with prediabetes (P = 0.01).
Overall prevalence of subjects with LGE was low but significantly higher in subjects with prediabetes and diabetes as compared with controls (7 and 5%, vs. 2%, P = 0.02 and P = 0.009, respectively).
LGE was detected in 26 segments of the overall 8 subjects with presence of LGE. LGE was detected in the sub-endocardial and mid-myocardial wall layer or transmurally (6/8, 75%) whereas subepicardial or exclusive mid-myocardial enhancement was detected in 25% (2/8). There was no difference with respect to native T1 relaxation times or the myocardial partition coefficient k between subjects with prediabetes, diabetes, and healthy controls (all P > 0.05; Table 2 ).
ECV was decreased in subjects with prediabetes and diabetes as compared with controls (23.1 ± 2.4 and 22.8 ± 3.0% vs. 24.2 ± 2.8%, P = 0.007 and P = 0.003, respectively). In addition, there was no difference in fibrosis volume between subjects with prediabetes, diabetes, and controls. In contrast, cell volume was significantly higher in subjects with prediabetes or diabetes as compared with controls (109.1 ± 23.8 and 114.9 ± 32.3 mL vs. 96.2 ± 26.9 mL, P = 0.03 and P = 0.003, respectively; Figure 2) .
Among available covariates, BMI and hypertension were predictive for ECV (b: -0.23, 95% CI: -0.30 to -0. 16 
Discussion
We performed a comprehensive CMR protocol in subjects with prediabetes, diabetes, and normal controls and preserved LVEF fraction from the general population. Our results indicate that subjects with prediabetes and diabetes have an increased LV remodelling index as compared with controls.
Diabetes status as well as hypertensive heart disease and obesity are correlated with myocardial fibrosis, concentric LV remodelling and hypertrophy of the left ventricle, which may lead to systolic or diastolic dysfunction. 7, 28 There is a large body of evidence that even prediabetes is associated with mild diastolic dysfunction and cardiac hypertrophy due to abnormal glucose metabolism.
5,29,30
In a cohort free of clinical cardiovascular disease, Heckbert et al.
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found that diabetes was associated with increased LV mass (3.5 g, 95% CI: 1.2-5.8), and lower LVEF (-0.8%, 95% CI: -1.5 to -0.2). Furthermore, Velagaleti et al. 29 showed that concentric LV remodelling index is significantly increased in subjects with prediabetes and diabetes, however, after inclusion of BMI, these associations were attenuated. In contrary, Shah et al. 32 demonstrated an association among insulin resistance, central obesity and concentric LV remodelling across BMI, independent of metabolic risk factors. These results support the assumption that even prediabetes status mediates concentric LV remodelling independently of BMI. We confirm these observations of significantly higher values of the LV remodelling index in subjects with prediabetes and diabetes compared with healthy controls, induced by increased LV mass and decreased end-diastolic LV volume in patients with prediabetes and diabetes compared with the control group. Our study results showed that LV remodelling index was significantly higher in subjects with prediabetes and diabetes, independent of metabolic risk factors like BMI, hypertension, sex, and age. Furthermore, recent research suggested that cardiac steatosis may be an independent predictor of concentric remodelling and systolic strain in patients with diabetes, in the absence of diffuse fibrosis in non-hypertensive patients with diabetes. 33 However, lipomatous metaplasia of the myocardium and mixture of fat and water in the same voxel may cause artefacts in widely used T1 mapping protocols and may affect interpretation of the myocardial tissue composition. 34 Considering the fact that our study population includes rather healthy subjects without prior cardiovascular diseases or impaired LV function, our findings extend current knowledge to indicate that the LV remodelling index may serve as a potential CMR based biomarker of myocardial changes even in subclinical stages of diabetes. LGE is strongly associated with adverse cardiac events in patients with prediabetes and diabetes status. 30 Kwong et al. 35 found a fourfold higher risk in patients with diabetes and present LGE. Our findings are in line with these observations, as we observed a significant difference of LGE between participants with diabetes and healthy controls. Thus, LGE may confer a highly relevant predictive value with an increased risk for adverse cardiac events. CMR-derived ECV reflects the presence and extent of myocardial fibrosis and correlates well with histological findings. 8, 36 Several studies indicate that ECV levels also represent an important prognostic value for risk stratification in patients for example with diabetes mellitus, since myocardial fibrosis measured by ECV is strongly associated with hospitalization for heart failure and death. 10, 11, 37 There is early evidence that diabetic cardiomyopathy is associated with higher ECV levels, indicating diffuse myocardial fibrosis. 9, 38, 39 For instance, Wong et al. 37 found an association of diabetes and elevated levels of ECV.
Similar observations were made by Jellis et al. 40 suggesting myocardial fibrosis as a contributor to the pathogenesis of diabetic cardiomyopathy. One explanation for the observed differences may be that the majority of these studies enrolled patients with prior cardiovascular diseases with a high percentage of hypertensive subjects and only a small proportion of patients with subclinical disease states such as prediabetes. Notably, our results showed inverse association between ECV and diabetes status, which attenuated after adjusting for hypertension and other metabolic risk factors. Furthermore, concomitant diseases such as hypertensive heart disease may have influenced differences in ECV, as differences in ECV values between the subgroups attenuated after the adjustment for metabolic risk factors such as hypertension and the proportion of subjects with hypertensive disease was high (70% of patients with diabetes and 44% of patients with prediabetes vs. 22% of controls, respectively). These facts may suggest that also hypertension may explain differences in ECV between subgroups, which is also in line with prior research indicating an association of significantly higher ECV values in patients with hypertensive heart disease as compared with non-hypertensive subjects. 7 On the contrary, we found higher cell volume levels in subjects with diabetes and prediabetes as compared with healthy controls, however, this association was attenuated after adjusting for cardiometabolic risk factors, including age, sex, BMI, and hypertension. Early findings in biopsied myocardium of diabetic patients with preserved LVEF suggested that beside interstitial myocardial fibrosis, hypertrophy of myocardial cells appears to be associated with diabetes status, even in early stages of the disease. 41, 42 These results indicate different stages in the development of diabetic cardiomyopathy. In a priori study, Rodrigues et al. 7 found concentric LV hypertrophy resulted from increased cell volume in hypertensive LV phenotypes, suggesting that rather hypertension than diabetic state is associated with increased cell volume in their population. Our results indicate that, after the adjustment for hypertension, LV remodelling index remained significantly higher in patients with diabetes and prediabetes, which indicates a detectable remodelling of the left ventricle even in patients with prediabetes, independent of metabolic risk factors such as age, hypertension, or BMI. Again, it needs to be highlighted that subjects with diabetes and prediabetes had significantly lower ECV values compared with controls in univariate analysis. Besides the presence of confounding factors, such as hypertension and BMI, one alternative explanation may be attributed to the fact that our study population represents a western population, which is often under appropriate cardioprotective medication, particularly in subjects with diabetes. The majority of the participants were currently treated with cardioprotective medication, including antihypertensive drugs or lipid-lowering agents. As such, these may have significantly impacted on the development of myocardial changes as, for instance, inhibitors of the angiotensin-converting enzyme are associated with regression of myocardial fibrosis and lower ECV levels. 37, 43 Moreover, the derived ECV measurements ranged from $25% in the control group to $23% in prediabetes and diabetes subjects, corresponding to relatively low ECV values when compared with other studies such as Schelbert et al. 10 (median of 28%, range: 17-48%) in a healthy study cohort. As a consequence, it may be assumed that our study population reflects a sample of the general, rather healthy population with preserved cardiac function, even in the diabetes subjects, which may be evident by the fact that nearly all of our subjects had an EF >50%. However, ECV and cell volume parameters were available in 251 subjects only (184 controls, 39 patients with prediabetes and 28 patients with diabetes, respectively) due to missing haematocrit values, which may limit the statistical power concerning the interpretation of the influence of changes in ECV and cell volume parameters to the development of diabetic cardiomyopathy. This study has several limitations. First, our study cohort is limited by a relatively small sample size, particularly in subjects in whom ECV, cell volume, and fibrosis volume measurements were available, as haematocrit levels were obtained in 251 subjects only. Postcontrast T1 maps were acquired 10 min after the application of the contrast medium. While this is not in line with currently existing guidelines, which recommend post-contrast T1 map acquisition 15 min after the administration of the contrast agent, 24 the study protocol was designed prior to statement availability. Also, all study participants underwent a similar CMR protocol, which would allow for intergroup comparisons, independent of post-contrast acquisition time. Our study is the largest of its nature and our results are rather hypothesis-generating than of confirmatory nature and further research will be necessary to confirm and extend our findings. We conclude that in subjects from a western, general population, subjects with prediabetes and diabetes have higher LV remodelling indices as compared with controls, suggesting early detectable changes in the disease process, while diffuse myocardial fibrosis appears to be less relevant at this stage. Furthermore, myocardial tissue changes in patients with hypertensive heart disease or patients with impaired glucose metabolism seem to underlie a complex mechanism, suggesting a progressive alteration of the myocardium in course of disease process. Presumably, the decrease of ECV as well as myocardial cell hypertrophy and concentric LV remodelling with reduced LV end-diastolic volume may be consistent with early disease stages, whereas increased ECV and thus an increase in fibrotic changes mostly appear at later stage of disease process. 7 However, further cohort-based confirmatory studies are clearly warranted.
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